Zacks Investment Research
12 Jun 2026, 14:51 UTC · 2h ago
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
12 Jun 2026, 14:51 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
Immuneering has dosed the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer. — Entering a pivotal Phase III trial is a major regulatory milestone that significantly increases the probability of future commercialization for a high-unmet-need indication.
+0.60Which stocks this story touches
Stock rose following the commencement of a pivotal phase III clinical study.
Continue reading
6 related stories
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
10h ago
